Surprisingly, <i>in vivo</i> results revealed the opposite trend: Her2-shIF1 CAR-T cells exhibited superior tumor inhibition, while Her2-IF1 CAR-T cells showed reduced efficacy despite their prolonged persistence. This evidence concerns the gene ERBB2 and neoplasm.